Caredx vs Starling Oncology
Starling Oncology is the larger business, with $503m of revenue in fiscal 2025 against $380m for Caredx (1.3 times as much). Starling Oncology grew faster (27.8% against 13.8%). Caredx kept more of each dollar of sales as profit: a net margin of -5.6% against -12.1%.
| Latest fiscal year | CaredxCDNA, 2025 | Starling OncologySTLN, 2025 |
|---|---|---|
| Revenue | $380m | $503m |
| Revenue growth | 13.8% | 27.8% |
| Net income | −$21.4m | −$60.6m |
| Operating margin | — | — |
| Net margin | -5.6% | -12.1% |
| Return on equity | -6.3% | — |
| Free cash flow | $42.0m | −$27.8m |
| Cash | $65.4m | $33.6m |
| Total debt | $0 | $85.9m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $87.8m | — |
| Employees | 765 | 641 |
| Market value | $4.66bn | $633m |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 26 sales | 16 buys, 11 sales |